ASE · Financial Statements
Kairos Pharma, Ltd. (KAPA) Financial Statements
$0.94
ASE: KAPA
Market Cap $2.88M
Overview Financials Dividend Kairos Pharma, Ltd. most recently reported annual revenue of $0, net profit of $-5.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025 Revenue $0 $0 $0 $0 $0 Operating Profit $-2.0M $-1.0M $-2.0M $-2.0M $-6.0M Net Profit $-2.0M $-1.0M $-2.0M $-3.0M $-5.0M EPS $-1.19 $-0.70 $-1.19 $-1.61 $-2.10 Op Margin — — — — —
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025 Total Assets $1.0M $1.0M $1.0M $6.0M $7.0M Total Liabilities $2.0M $2.0M $3.0M $1.0M $0 Cash $0 $0 $0 $1.0M $4.0M Borrowings $0 $1.0M $1.0M $0 $0
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025 Operating Cash Flow $0 $0 $0 $-4.0M $-3.0M Investing Cash Flow $0 $0 $0 $0 $0 Financing Cash Flow $0 $0 $0 $0 $4.0M Net Cash Flow $0 $0 $0 $1.0M $3.0M Free Cash Flow $0 $0 $0 $-4.0M $-3.0M
Valuation & Return Ratios
Metric Value PEG Ratio -0.05 EV / EBITDA -0.38 FCF Yield -83.20% Quick Ratio 11.98 Interest Coverage 0.00 Return 1Y -72.82% Return 3Y — Return 5Y —
Screens featuring this stock